Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

NCT01779206 is registered in ClinicalTrials.gov with Women's Cancer Study Group GmbH as lead sponsor.

NCT NCT01779206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01779206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Lead sponsor
Women's Cancer Study Group GmbH
Phase
Phase 2/3
Overall status
Completed
Start date
May 31, 2012
Completion date
January 15, 2025
Enrollment
4,936 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer